Hantz Financial Services Inc. Purchases 115,184 Shares of DexCom, Inc. (NASDAQ:DXCM)

Hantz Financial Services Inc. grew its position in DexCom, Inc. (NASDAQ:DXCM) by 12,699.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 116,091 shares of the medical device company’s stock after buying an additional 115,184 shares during the period. Hantz Financial Services Inc.’s holdings in DexCom were worth $9,028,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jennison Associates LLC boosted its stake in DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after acquiring an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of DexCom by 182.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after purchasing an additional 739,000 shares in the last quarter. Intech Investment Management LLC grew its stake in DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after buying an additional 369,587 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in DexCom by 53.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after buying an additional 345,114 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Down 2.2 %

Shares of DXCM stock opened at $86.43 on Thursday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market cap of $33.76 billion, a price-to-earnings ratio of 51.75, a PEG ratio of 2.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a 50 day simple moving average of $80.00 and a 200-day simple moving average of $76.52.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group boosted their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Leerink Partners decreased their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein boosted their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.